Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: A national study

Drug and Alcohol Dependence

Volumn 132, Issue 1-2, 2013, Pages 122-126

  Iheanacho, Theddeus ^a   Issa, Mohammed ^a   Marienfeld, Carla ^a   Rosenheck, Robert ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA New England Mental Illness Research and Education Center   (United States)

Author keywords

Alcohol; Co morbidity; Naltrexone; Prescription; Sociodemographic factors; VA; Veteran's Administration

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC AGENT; NALTREXONE; NEUROLEPTIC AGENT; SEDATIVE AGENT;

ADULT; ALCOHOL USE DISORDER; ALCOHOLISM; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH CARE; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; VETERAN;

ALCOHOL; CO-MORBIDITY; NALTREXONE; PRESCRIPTION; SOCIODEMOGRAPHIC FACTORS; VA; VETERAN'S ADMINISTRATION;

ADULT; AGED; ALCOHOLISM; ANALYSIS OF VARIANCE; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); DRUG UTILIZATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MENTAL DISORDERS; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; SOCIOECONOMIC FACTORS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84881660420     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.01.016     Document Type: Article

References (24)

1. Garbutt J.C., West S.L., Carey T.S., Lohr K.N., Crews F.T. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999, 281:1318-1325.
2. Grant B.F., Dawson D.A., Stinson F.S., Chou S.P., Dufour M.C., Pickering R.P. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend. 2004, 74:223-234.
3. Harris A.H., Kivlahan D.R., Bowe T., Humphreys K.N. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr. Serv. 2010, 61:392-398.
4. Harris K.M., DeVries A., Dimidjian K. Datapoints: trends in naltrexone use among members of a large private health plan. Psychiatr. Serv. 2004, 55:221.
5. Jacobson I.G., Ryan M.A., Hooper T.I., Smith T.C., Amoroso P.J., Boyko E.J., Gackstetter G.D., Wells T.S., Bell N.S. Alcohol use and alcohol-related problems before and after military combat deployment. JAMA 2008, 300:663-675.
6. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P., Holzbach R., Kämpf P., Stracke R., Baehr M., Naber D., Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2003, 60:92-99.
7. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., Rosenheck R.A., Group V.A.N.C.S. Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med. 2001, 345:1734-1739.
8. Laaksonen E., Koski-Jännes A., Salaspuro M., Ahtinen H., Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2008, 43:53-61.
9. Mark T.L., Kranzler H.R., Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 2003, 71:219-228.
10. Moos R.H., Moos B.S. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction 2006, 101:212-222.
11. Morley K.C., Teesson M., Reid S.C., Sannibale C., Thomson C., Phung N., Weltman M., Bell J.R., Richardson K., Haber P.S. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006, 101:1451-1462.
12. Petrakis I.L., Leslie D., Rosenheck R. Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs. Alcohol. Clin. Exp. Res. 2003, 27:1780-1784.
13. Petrakis I.L., Nich C., Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr. Bull. 2006, 32:644-654.
14. Petrakis I.L., O'Malley S., Rounsaville B., Poling J., McHugh-Strong C., Krystal J.H., Group V.N.S.C. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl.) 2004, 172:291-297.
15. Petrakis I.L., Poling J., Levinson C., Nich C., Carroll K., Ralevski E., Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol. Psychiatry 2006, 60:777-783.
16. Petrakis I.L., Poling J., Levinson C., Nich C., Carroll K., Rounsaville B., VA New England VISN I MIRECC Study Group Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol. Psychiatry 2005, 57:1128-1137.
17. Pettinati H.M., O'Brien C.P., Rabinowitz A.R., Wortman S.P., Oslin D.W., Kampman K.M., Dackis C.A. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J. Clin. Psychopharmacol. 2006, 26:610-625.
18. Rehm J., Mathers C., Popova S., Thavorncharoensap M., Teerawattananon Y., Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009, 373:2223-2233.
19. Rösner S., Hackl-Herrwerth A., Leucht S., Vecchi S., Srisurapanont M., Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev. 2010, CD001867.
20. Seal K.H., Metzler T.J., Gima K.S., Bertenthal D., Maguen S., Marmar C.R. Trends and risk factors for mental health diagnoses among Iraq and Afghanistan veterans using Department of Veterans Affairs health care, 2002-2008. Am. J. Public Health 2009, 99:1651-1658.
21. West S.L., Garbutt J.C., Carey T.S., Lux L.J., Jackman A.M., Tolleson-Rinehart S., Lohr K.N., Crews F.T. Pharmacotherapy for alcohol dependence. Evid. Rep. Technol. Assess. (Summ.) 1999, 1-5.
22. Williams S.H. Medications for treating alcohol dependence. Am. Fam. Physician 2005, 72:1775-1780.
23. Witkiewitz K., Saville K., Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther. Clin. Risk Manag. 2012, 8:45-53.
24. Zarkin G.A., Bray J.W., Aldridge A., Mitra D., Mills M.J., Couper D.J., Cisler R.A., COMBINE Cost-Effectiveness Research Group Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. Arch. Gen. Psychiatry 2008, 65:1214-1221.